|
Language for communicating frequentist results about treatment effects
|
|
179
|
36477
|
January 12, 2021
|
|
Multiplicity in clinical trials with hierarchical strategy
|
|
2
|
180
|
December 30, 2020
|
|
What is a fake measurement tool and how are they used in RCT
|
|
44
|
1675
|
December 20, 2020
|
|
Quality of remdesivir trials
|
|
41
|
2758
|
November 18, 2020
|
|
RCT trials for COVID study vaccines
|
|
0
|
292
|
October 24, 2020
|
|
Can treatment B be superior after the RCT if it was thought that treatment A is superior before the RCT?
|
|
5
|
546
|
October 13, 2020
|
|
"Open label, double-masked trial"
|
|
0
|
359
|
October 13, 2020
|
|
ANCOVA with randomized and nonrandomized groups
|
|
4
|
513
|
September 30, 2020
|
|
Time since randomization and causality
|
|
2
|
383
|
September 27, 2020
|
|
Bayesian Solutions for Challenges to Frequentist Statistics
|
|
0
|
1298
|
September 22, 2020
|
|
Empirical Bayes for RCT Interpretarion
|
|
8
|
1961
|
August 11, 2020
|
|
Re-starting a Bayesian group sequential design trial after stopping it
|
|
4
|
528
|
August 11, 2020
|
|
MERINO trial - adjusting for infection source
|
|
3
|
702
|
August 3, 2020
|
|
Thoughts on 'representativeness' and 'generalizability'
|
|
6
|
1015
|
July 19, 2020
|
|
Interpretation of INTERACT-2 Study in Intracerebral Hemorrhage
|
|
3
|
789
|
June 15, 2020
|
|
First RCT of Lopinavir–Ritonavir on SARS-CoV2
|
|
37
|
6625
|
May 19, 2020
|
|
Open-label RCT of triple combination (LPV/r, Ribavirin, Interferon) on SARS-CoV2
|
|
1
|
1014
|
May 15, 2020
|
|
Type I error in a specific design of 2-parallel group study
|
|
3
|
1142
|
March 11, 2020
|
|
RCT generalizability and interactions with treatment
|
|
8
|
1560
|
March 10, 2020
|
|
Presenting models of multiple (potentially recurring) outcomes
|
|
1
|
810
|
March 6, 2020
|
|
Power for interaction effects
|
|
6
|
1111
|
February 24, 2020
|
|
Open label RCT: Placebo or Real effect?
|
|
5
|
1417
|
February 5, 2020
|
|
Handling withdrawn study subjects
|
|
6
|
1081
|
February 4, 2020
|
|
Marginal vs conditional (Mixed) models used in Joint model analysis. The SPRINT trial controversy
|
|
9
|
3940
|
December 2, 2019
|
|
2019 Nobel Prize in Economic Sciences is about limitations of RCT
|
|
15
|
2259
|
November 5, 2019
|
|
Adherence adjustment in randomized trials is possible, here's why
|
|
4
|
2795
|
July 9, 2019
|
|
RCT ceiling effects and high drop off rate
|
|
6
|
1553
|
October 14, 2019
|
|
How much patient variability is best for a clinical trial?
|
|
5
|
1553
|
September 22, 2019
|
|
Deviation in primary endpoint definition
|
|
12
|
1540
|
July 26, 2019
|
|
Advice/Opinion on (reviewing - ethics) an RCT analysis plan
|
|
1
|
1184
|
June 28, 2019
|
